Cervical Squamous Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CRV038 MIFTS: 60	Cervical Squamous Cell Carcinoma Categories: Cancer diseases, Rare diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Cervical Squamous Cell Carcinoma

MalaCards integrated aliases for Cervical Squamous Cell Carcinoma:

Name: Cervical Squamous Cell Carcinoma ¹¹ ⁵⁸ ⁵³ ¹⁴ ¹⁶ ⁷¹

Squamous Cell Carcinoma of the Cervix Uteri ¹¹ ⁵⁸

Squamous Cell Carcinoma of Cervix ¹¹

Characteristics:

Prevelance:

Squamous Cell Carcinoma of the Cervix Uteri: 1-9/100000 (Europe, Austria, Belgium, Croatia, Czech Republic, Finland, Germany, Iceland, Ireland, Italy, Latvia, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands, United Kingdom) 1-5/10000 (Bulgaria, Estonia, Lithuania) ⁵⁸

Age Of Onset:

Squamous Cell Carcinoma of the Cervix Uteri: Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of cervix uteri

Malignant neoplasm: Endocervix

Malignant neoplasm: Exocervix

Malignant neoplasm: Overlapping lesion of cervix uteri

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of female genital organs

Malignant neoplasms of cervix uteri

Squamous cell carcinoma of cervix uteri

Orphanet: ⁵⁸

Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology ¹¹ DOID:3744

NCIt ⁴⁹ C4028

SNOMED-CT ⁶⁸ 254886006

ICD10 via Orphanet ³² C53.0 C53.1 C53.8

UMLS via Orphanet ⁷² C0279671

Orphanet ⁵⁸ ORPHA213767

EFO ¹⁶ EFO_1000172

ICD11 ³³ 1544785014

UMLS ⁷¹ C0279671

Sources

Summaries for Cervical Squamous Cell Carcinoma

Disease Ontology: ¹¹ A cervix carcinoma that has material basis in squamous cells of the cervix.

MalaCards based summary: Cervical Squamous Cell Carcinoma, also known as squamous cell carcinoma of the cervix uteri, is related to squamous cell carcinoma and suppressor of tumorigenicity 3. An important gene associated with Cervical Squamous Cell Carcinoma is LOC105379013 (Uncharacterized LOC105379013), and among its related pathways/superpathways are Regulation of TP53 Activity and TNFR1 Pathway. The drugs Topotecan and Vinorelbine have been mentioned in the context of this disorder. Affiliated tissues include cervix, uterus and lymph node, and related phenotypes are endocrine/exocrine gland and cellular

Sources

Related Diseases for Cervical Squamous Cell Carcinoma

Diseases related to Cervical Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 263)

#	Related Disease	Score	Top Affiliating Genes
1	squamous cell carcinoma	32.4	TP73 TP63 TP53 SERPINB3 PIK3CA DAPK1
2	suppressor of tumorigenicity 3	31.9	TP53 CDKN2A
3	cervical cancer	31.5	TYMP TP73 TP63 TP53 SERPINB3 RASSF1
4	adenocarcinoma	31.5	TYMP TP53 TIMP2 PIK3CA MLH1 CDKN2A
5	endocervical adenocarcinoma	31.4	TP53 PIK3CA CDKN2A
6	papilloma	31.4	TP63 TP53 RASSF1 KRT8 CDKN2A
7	cervical adenocarcinoma	31.4	TP53 RASSF1 KRT8 CDKN2A
8	chronic cervicitis	31.2	TP53 CDKN2A
9	mixed cell type cancer	31.0	TP53 PIK3CA MLH1 CDKN2A
10	penile cancer	31.0	TP53 RASSF1 PIK3CA CDKN2A
11	endometrial adenocarcinoma	31.0	TP53 MLH1 CDKN2A
12	human papillomavirus infectious disease	31.0	TP53 PIK3CA CDKN2A
13	carcinosarcoma	30.9	TP53 PIK3CA CDKN2A
14	keratinizing squamous cell carcinoma	30.9	TP53 PIK3CA CDKN2A
15	adenoid cystic carcinoma	30.9	TP63 TP53 RASSF1 PIK3CA DAPK1 CDKN2A
16	anal squamous cell carcinoma	30.8	TP53 PIK3CA CDKN2A
17	basaloid squamous cell carcinoma	30.8	TP53 KRT8 CDKN2A
18	keratoacanthoma	30.8	TP63 TP53 PIK3CA MLH1 KRT8
19	endocervical carcinoma	30.7	TP53 PIK3CA CDKN2A
20	muir-torre syndrome	30.7	TP53 MLH1 CDKN2A
21	ovary adenocarcinoma	30.6	TP53 PIK3CA MLH1 CDKN2A
22	uterine carcinosarcoma	30.6	TP53 PIK3CA MLH1 KRT8
23	breast adenocarcinoma	30.6	TP53 PIK3CA KRT8 CDKN2A
24	transitional cell carcinoma	30.6	TP63 TP53 MMP14 MLH1 DAPK1
25	microinvasive gastric cancer	30.6	XIST TP53 MLH1
26	endometrial cancer	30.4	TYMP TP73 TP53 TIMP2 RASSF1 PIK3CA
27	esophageal cancer	30.3	TYMP TP73 TP53 PIK3CA MMP14 MLH1
28	melanoma	30.1	XIST TP53 TIMP2 RASSF1 PIK3CA MMP14
29	breast cancer	30.1	XIST TYMP TP73 TP63 TP53 TIMP2
30	ovarian cancer	30.0	XIST TYMP TP73 TP53 TIMP2 SKP2
31	hepatocellular carcinoma	29.4	XIST TYMP TP73 TP53 TIMP2 SKP2
32	microinvasive cervical squamous cell carcinoma	11.8
33	cervical verrucous carcinoma	11.3
34	cervical basaloid squamous cell carcinoma	11.3
35	cervical keratinizing squamous cell carcinoma	11.3
36	cervical lymphoepithelioma-like carcinoma	11.3
37	cervical intraepithelial neoplasia	10.8
38	cervix uteri carcinoma in situ	10.5
39	acanthoma	10.5	TP53 PIK3CA CDKN2A
40	esophagus verrucous carcinoma	10.5	TP53 PIK3CA CDKN2A
41	verrucous carcinoma	10.5	TP53 PIK3CA CDKN2A
42	penile benign neoplasm	10.5	TP53 PIK3CA CDKN2A
43	b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)	10.5	TP53 CDKN2A
44	endometrial squamous cell carcinoma	10.5	TP53 CDKN2A
45	vulva squamous cell carcinoma	10.5	TP53 PIK3CA CDKN2A
46	laryngeal benign neoplasm	10.5	TP53 PIK3CA CDKN2A
47	vulvar disease	10.5	TP53 PIK3CA CDKN2A
48	anus cancer	10.5	TP53 PIK3CA CDKN2A
49	vaginal carcinosarcoma	10.5	TP53 PIK3CA
50	keratosis, seborrheic	10.5	TP53 PIK3CA CDKN2A

Graphical network of the top 20 diseases related to Cervical Squamous Cell Carcinoma:

Sources

Symptoms & Phenotypes for Cervical Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Cervical Squamous Cell Carcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland	MP:0005379	10.06	CDKN2A MLH1 MMP14 PIK3CA RASSF1 SERPINB3
2	cellular	MP:0005384	9.93	CDKN2A DAPK1 MLH1 MMP14 PIK3CA RASSF1
3	neoplasm	MP:0002006	9.91	CDKN2A MLH1 PIK3CA RASSF1 TP53 TP63
4	digestive/alimentary	MP:0005381	9.91	CDKN2A KRT8 MLH1 MMP14 PIK3CA RASSF1
5	immune system	MP:0005387	9.8	CDKN2A KRT8 MLH1 MMP14 PIK3CA RASSF1
6	reproductive system	MP:0005389	9.36	CDKN2A KRT8 MLH1 MMP14 PIK3CA SERPINB3

Sources

Drugs & Therapeutics for Cervical Squamous Cell Carcinoma

Drugs for Cervical Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Topotecan

Approved, Investigational

Phase 3

123948-87-8, 119413-54-6

60699 60700

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

44424639 60780

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Tirapazamine

Investigational

Phase 3

27314-97-2

135413511

Antiviral Agents

Phase 3

Anti-Infective Agents

Phase 3

Antimetabolites

Phase 3

topoisomerase I inhibitors

Phase 3

Epoetin Alfa

Phase 3

Hematinics

Phase 3

Chrysarobin

Phase 3

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Mitomycin

Approved

Phase 2

50-07-7

5746

Ipilimumab

Approved

Phase 2

477202-00-9

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Cetuximab

Approved

Phase 2

205923-56-4

Erlotinib

Approved, Investigational

Phase 2

183319-69-9, 183321-74-6

176870

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Indomethacin

Approved, Investigational

Phase 2

53-86-1

3715

Zinc cation

Approved, Experimental, Investigational

Phase 2

7440-66-6, 23713-49-7

32051

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Esomeprazole

Approved, Investigational, Vet_approved

Phase 2

73590-58-6, 119141-88-7

9568614 4594

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

133585-56-5, 60-18-4, 556-02-5

1153 6057

Veliparib

Investigational

Phase 2

912444-00-9

11960529

Albumin-Bound Paclitaxel

Phase 2

Immunoglobulins, Intravenous

Phase 2

Immunoglobulins

Phase 2

Immunoglobulin G

Phase 2

Immune Checkpoint Inhibitors

Phase 2

Antibodies, Monoclonal

Phase 2

Antibodies

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Immunologic Factors

Phase 2

Fluorodeoxyglucose F18

Phase 1, Phase 2

Angiogenesis Inhibitors

Phase 2

Endothelial Growth Factors

Phase 2

Mitogens

Phase 2

Protein Kinase Inhibitors

Phase 2

Anti-Bacterial Agents

Phase 2

Antifungal Agents

Phase 2

Antibiotics, Antitubercular

Phase 2

Adjuvants, Immunologic

Phase 2

Interventional clinical trials:

(show top 50) (show all 67)

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix	Completed	NCT00803062	Phase 3	Cisplatin;Paclitaxel;Topotecan Hydrochloride
2	Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer	Completed	NCT00017004	Phase 3	Cisplatin
3	A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix	Completed	NCT00064077	Phase 3	Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4	A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial	Completed	NCT01414608	Phase 3	Carboplatin;Cisplatin;Paclitaxel
5	A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy	Completed	NCT01365156	Phase 3
6	Study of Two Fractions Versus Three Fractions High Dose Rate Brachytherapy in Locally Advanced Carcinoma of Uterine Cervix After Pelvic Concurrent Chemoradiotherapy - a Randomized Controlled Trial	Completed	NCT02765919	Phase 3
7	Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)	Active, not recruiting	NCT01101451	Phase 3	Cisplatin
8	A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer	Active, not recruiting	NCT02466971	Phase 3	Cisplatin;Triapine
9	A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis	Terminated	NCT00262821	Phase 3	cisplatin;tirapazamine
10	Efficacy and Safety of Nimotuzumab Combined With Radiotherapy and Concurrently Cisplatin in Patients With Stage IIB-IVA Cervical Squamous Cell Carcinoma	Unknown status	NCT03469531	Phase 2	Nimotuzumab;Cisplatin
11	Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer (SIDE, Advanced Squamous Cervical Cancer Trial)	Unknown status	NCT02879214	Phase 2
12	A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA	Completed	NCT00369122	Phase 2	Cisplatin
13	A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies	Completed	NCT01693783	Phase 2
14	A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Cervical Cancer	Completed	NCT00559377	Phase 2
15	A Simplified Approach of Complete Nerve-sparing Type C1 Radical Hysterectomy for Cervical Cancer, a Phase II Study	Completed	NCT02562729	Phase 2
16	Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage	Completed	NCT00416455	Phase 1, Phase 2	ferumoxtran-10
17	A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma	Completed	NCT00389974	Phase 2	sunitinib malate
18	A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix	Completed	NCT00499031	Phase 2
19	A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix	Completed	NCT00041093	Phase 2	Docetaxel
20	A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix	Completed	NCT00031993	Phase 2	erlotinib hydrochloride
21	A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer	Completed	NCT00057863	Phase 2	Paclitaxel;Oxaliplatin
22	A Phase II Trial of Bevacizumab (rhuMAB VEGF) (NSC #704865) in the Treatment of Persistent and Recurrent Squamous Cell Carcinoma of the Cervix (Group A)	Completed	NCT00025233	Phase 2
23	Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer	Completed	NCT00217633	Phase 2
24	A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix	Completed	NCT00309959	Phase 2	Paclitaxel Albumin-Stabilized Nanoparticle Formulation
25	A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix	Completed	NCT01026792	Phase 2	Temsirolimus
26	A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix	Completed	NCT01266460	Phase 2
27	A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix	Completed	NCT01266447	Phase 2	Topotecan Hydrochloride;Veliparib
28	A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)	Completed	NCT01267253	Phase 2	Brivanib Alaninate
29	A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer	Completed	NCT02921269	Phase 2	Atezolizumab
30	PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX	Completed	NCT02164461	Phase 1, Phase 2
31	A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma	Completed	NCT01807546	Phase 2	rigosertib
32	A Phase II Open-Label, Single Arm Pilot Study to Evaluate the Safety and Efficacy of Pembrolizumab for High-Grade Cervical Intraepithelial Neoplasia	Recruiting	NCT04712851	Phase 2
33	IMMUNOCERV: Evaluating the Safety of Chemoradiation Combined With PDS0101 Immunotherapy in Treating Locally Advanced Cervical Cancer	Recruiting	NCT04580771	Phase 2	Cisplatin
34	A Two-Cohort Randomized Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)	Recruiting	NCT03267680	Phase 2	Cyclophosphamide;Indomethacin;Omeprazole
35	A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors	Active, not recruiting	NCT03074513	Phase 2	Atezolizumab
36	A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Paclitaxel and Carboplatin in HIV-positive Women With Locally Advanced Cervical Cancer (LACC)	Withdrawn	NCT03834571	Phase 2	Carboplatin;Cisplatin;Paclitaxel
37	A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes	Unknown status	NCT01295502	Phase 1	Carboplatin;Cisplatin;Paclitaxel
38	A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck	Completed	NCT02113878	Phase 1	BKM120;Cisplatin
39	A Phase I Trial of Tailored Radiation Therapy With Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients With Cervical Cancer	Completed	NCT00104910	Phase 1	Cisplatin
40	A PHASE I STUDY OF PELVIC RADIATION THERAPY WITH CONCOMITANT WEEKLY CISPLATIN AND TOPOTECAN CHEMOTHERAPY IN PATIENTS WITH CERVICAL CARCINOMA WITHOUT EXTRA-PELVIC METASTASIS	Completed	NCT00054444	Phase 1	Topotecan Hydrochloride Liposomes;Cisplatin
41	A Phase I Study of Whole Pelvic Radiation Therapy With Concomitant Cisplatin and Gemcitabine Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis	Completed	NCT00068549	Phase 1	Gemcitabine Hydrochloride;Cisplatin
42	A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix	Completed	NCT01281852	Phase 1	Cisplatin;Paclitaxel;Veliparib
43	A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients With Locally Advanced Cervical Cancer Stages IB2/IIA With Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA With Positive Lymph Nodes	Completed	NCT01711515	Phase 1	Cisplatin
44	Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer	Recruiting	NCT02595879	Phase 1	Cisplatin;Triapine
45	Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)	Recruiting	NCT02020707	Phase 1	Nab-paclitaxel
46	Phase I Multi-Center Study of Hypofractionated Radiotherapy in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer	Active, not recruiting	NCT03452332	Phase 1
47	Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer	Active, not recruiting	NCT03738228	Phase 1	Atezolizumab;Cisplatin
48	Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors	Active, not recruiting	NCT03983954	Phase 1
49	The Efficacy and Safety of Tislelizumab Combined With Taxanes and Platinum as Neoadjuvant Therapy for Patients With Local Advanced Cervical Carcinoma， an Open Lable，Single-center, Exploratory Clinical Trial	Not yet recruiting	NCT05013268	Phase 1	Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin
50	A Prospective Randomized Controlled Study of Radiotherapy and the Concurrent Three-week and Single-week TP Chemotherapy for Advanced Cervical Squamous Cell Carcinoma and the Correlation Between HPV Classification and Sensitivity.	Unknown status	NCT04588090

Search NIH Clinical Center for Cervical Squamous Cell Carcinoma

Sources

Genetic Tests for Cervical Squamous Cell Carcinoma

Sources

Anatomical Context for Cervical Squamous Cell Carcinoma

Organs/tissues related to Cervical Squamous Cell Carcinoma:

MalaCards : Cervix, Uterus, Lymph Node, Endothelial, T Cells, Breast, Lung

Sources

Publications for Cervical Squamous Cell Carcinoma

Articles related to Cervical Squamous Cell Carcinoma:

(show top 50) (show all 1705)

#	Title	Authors	PMID	Year
1	Usefulness of p16 for differentiating primary pulmonary squamous cell carcinoma from cervical squamous cell carcinoma metastatic to the lung. ⁵³ ⁶²	Wang CW...Chen TC	19369633	2009
2	Methylation of the RASSF1A gene promoter in Uigur women with cervical squamous cell carcinoma. ⁵³ ⁶²	Pan Z...Shao R	19366060	2009
3	[Expression of Skp2 in cervical squamous cell carcinoma and precancerous lesions and its correlation with HPV16/18 infection]. ⁵³ ⁶²	Pan BJ...Chen JW	19094580	2008
4	Coordinate expression of cytokeratin 8 and cytokeratin 17 immunohistochemical staining in cervical intraepithelial neoplasia and cervical squamous cell carcinoma: an immunohistochemical analysis and review of the literature. ⁵³ ⁶²	Ikeda K...Mitsuya T	18191996	2008
5	Relationship between decreased expression of squamous cell carcinoma antigen 2 and E-cadherin in primary cervical cancer lesions and lymph node metastasis. ⁵³ ⁶²	Murakami A...Sugino N	18097581	2008
6	Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. ⁵³ ⁶²	Choi CH...Kim BG	17467893	2007
7	Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. ⁵³ ⁶²	Manavi M...Czerwenka K	17306351	2007
8	Reverse transcription-polymerase chain reaction and western blotting analysis for detection of p63 isoforms in uterine cervical cancers. ⁵³ ⁶²	Lin Z...Kim I	16884378	2006
9	Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. ⁵³ ⁶²	Liu SS...Ngan HY	16818688	2006
10	EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. ⁵³ ⁶²	Sier CF...Gorter A	16425263	2006
11	Expression of thymidine phosphorylase as an effect prediction factor for uterine cervical squamous cell carcinoma after radiotherapy: an immunohistochemical study. ⁵³ ⁶²	Nakashima M...Kojima Y	16803522	2006
12	[Expression of key cell cycle markers in squamous cell carcinoma of the cervix positive in human papillomavirus: a comparative study between Chinese and Australian populations]. ⁵³ ⁶²	Liu JH...Li W	16677523	2006
13	Reduced radiosensitivity and increased CD40 expression in cyclophosphamide-resistant subclones established from human cervical squamous cell carcinoma cells. ⁵³ ⁶²	Tanaka T...Umesaki N	16142355	2005
14	Radiation-induced cell death is independent of the apoptotic signals mediated by death-associated protein kinase in human cervical squamous cell carcinoma cells. ⁵³ ⁶²	Tanaka T...Umesaki N	16142356	2005
15	Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. ⁵³ ⁶²	Shurin GV...Shurin MR	15843547	2005
16	Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma. ⁵³ ⁶²	Oguri H...Fukaya T	14614573	2004
17	P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. ⁵³ ⁶²	Cho NH...Song KJ	14599865	2003
18	Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy. ⁵³ ⁶²	Oka K...Nakano T	12909236	2003
19	Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis. ⁵³ ⁶²	Yuan CC...Chiu LM	11876385	2002
20	Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis. ⁵³ ⁶²	Fujiwaki R...Miyazaki K	10810442	2000
21	Expression of topoisomerase II and Ki-67 in cervical carcinoma--clinicopathological study using immunohistochemistry. ⁵³ ⁶²	Davidson B...Kopolovic J	10752690	2000
22	Thymidine phosphorylase expression in tumor stroma of uterine cervical carcinomas: histological features and microvessel density. ⁵³ ⁶²	Tang W...Kakudo K	10695991	2000
23	Immunohistochemical and DNA sequencing analysis on human mismatch repair gene MLH1 in cervical squamous cell carcinoma with LOH of this gene. ⁵³ ⁶²	Hu X...Ponten J	10769651	2000
24	Biological implications of growth factors on the mechanism of invasion in gynecological tumor cells. ⁵³ ⁶²	Ueda M...Nakajima M	10545752	1999
25	Fatty acid synthase (FASN) inhibits the cervical squamous cell carcinoma (CESC) progression through the Akt/mTOR signaling pathway. ⁶²	Lin Q...Zhang Y	36375657	2023
26	SOX2 expression in the pathogenesis of premalignant lesions of the uterine cervix: its histo-topographical distribution distinguishes between low- and high-grade CIN. ⁶²	Moshi JM...Hopman AHN	35945296	2022
27	Molecular Analysis of HPV-independent Primary Endometrial Squamous Cell Carcinoma Reveals TP53 and CDKN2A Comutations : A Clinicopathologic Analysis With Re-evaluation of Diagnostic Criteria. ⁶²	Hopkins MR...Murdock TA	36069815	2022
28	The regulation role and diagnostic value of fibrinogen-like protein 1 revealed by pan-cancer analysis. ⁶²	Yi W...Lv Z	36345363	2022
29	Convolutional Neural Networks for Classifying Cervical Cancer Types Using Histological Images. ⁶²	Li YX...Wang M	36474087	2022
30	Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype. ⁶²	Cohen CM...Clarke MA	36455190	2022
31	Identification of novel genetic and epigenetic regulators of different tissue types of cervical cancer. ⁶²	Chandra S...Mandal P	36184073	2022
32	Projectile vomiting as presentation of duodenal intramural metastasis from cervical cancer. ⁶²	Lin YH...Liu CY	36427973	2022
33	MiR-95-3p acts as a prognostic marker and promotes cervical cancer progression by targeting VCAM1. ⁶²	Feng S...Wang H	36467343	2022
34	MiR-99a-5p Constrains Epithelial-Mesenchymal Transition of Cervical Squamous Cell Carcinoma Via Targeting CDC25A/IL6. ⁶²	Gu A...Bao X	35532870	2022
35	Pembrolizumab Improves Survival After Resection of Intracardiac Metastatic Cervical Carcinoma. ⁶²	Steely AM...Chu LM	35090858	2022
36	Sequential gene expression analysis of cervical malignant transformation identifies RFC4 as a novel diagnostic and prognostic biomarker. ⁶²	Zhang J...Li S	36352434	2022
37	Prognostic significance of ferroptosis pathway gene signature and correlation with macrophage infiltration in cervical squamous cell carcinoma. ⁶²	Li CJ...Chiang AJ	36183678	2022
38	Curious Case of Superfitial Spreading Cervical Squamocellular Carcinoma with Adnexal Involvement. ⁶²	Dokic M...Kesic V	36422194	2022
39	CXCL10 serves as a potential serum biomarker complementing SCC-Ag for diagnosing cervical squamous cell carcinoma. ⁶²	Zhang J...Ren L	36207693	2022
40	Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance. ⁶²	Chakravarthy A...Fenton TR	36207323	2022
41	Can the combination of DWI and T2WI radiomics improve the diagnostic efficiency of cervical squamous cell carcinoma? ⁶²	Wang S...Zhao Z	35842193	2022
42	Identification and validation of serum tumor-markers based nomogram to predict the prognostic value of patients with cervical adenocarcinoma. ⁶²	Liu Y...Ye W	36270166	2022
43	RNPS1 functions as an oncogenic splicing factor in cervical cancer cells. ⁶²	Deka B...Singh KK	36300671	2022
44	Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification. ⁶²	Sun K...Luo ZX	36253777	2022
45	Glycogen synthase kinase-3β inactivation promotes cervical cancer progression, invasion, and drug resistance. ⁶²	Nath N...Mishra R	34554598	2022
46	Single-Nucleus RNA Sequencing and Spatial Transcriptomics Reveal the Immunological Microenvironment of Cervical Squamous Cell Carcinoma. ⁶²	Ou Z...Wu P	35986392	2022
47	The long-term outcomes of clinical responders to neoadjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer. ⁶²	Li W...Chen C	36269389	2022
48	hsa-mir-133a-2 promotes the proliferation and invasion of cervical cancer cells by targeting the LAMB3-mediated PI3K/ATK pathway. ⁶²	Sui X...Li X	36305754	2022
49	Fyn expression is associated with the response of patients with locally advanced uterine cervical squamous cell carcinoma to neoadjuvant chemotherapy. ⁶²	Nanno S...Sumi T	36157319	2022
50	Radiomic Analysis for Pretreatment Prediction of Recurrence Post-Radiotherapy in Cervical Squamous Cell Carcinoma Cancer. ⁶²	Kawahara D...Nagata Y	36292034	2022

Sources

Genes for Cervical Squamous Cell Carcinoma

Genes related to Cervical Squamous Cell Carcinoma (0 elite genes):

(show top 50) (show all 53)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	LOC105379013	Uncharacterized LOC105379013	RNA Gene	154.7	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29525275
2	BAIAP2-DT	BAIAP2 Divergent Transcript	RNA Gene	154.02	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29525275
3	XIST	X Inactive Specific Transcript	RNA Gene	153.68	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	27899965
4	ILF3-DT	ILF3 Divergent Transcript	RNA Gene	153.45	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29525275
5	LINC01133	Long Intergenic Non-Protein Coding RNA 1133	RNA Gene	153.03	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29525275
6	SERHL	Serine Hydrolase Like (Pseudogene)	Pseudogene	150	Experimental evidence: Expression ³⁷	29525275
7	TP53	Tumor Protein P53	Protein Coding	22.51	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
8	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	21.73	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
9	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	21.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19062717 12378514 17306351 (more) 16677523 15143339 19369633
10	SERPINB3	Serpin Family B Member 3	Protein Coding	20.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18097581 9817979 10873412
11	RASSF1	Ras Association Domain Family Member 1	Protein Coding	18.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19366060 17360030 17467893 (more) 15612586
12	TP63	Tumor Protein P63	Protein Coding	18.38	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16884378 14599865
13	DAPK1	Death Associated Protein Kinase 1	Protein Coding	18.22	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18799028 16142356
14	TYMP	Thymidine Phosphorylase	Protein Coding	17.85	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16803522 14614573 10695991 (more) 10810442 10545752 12909236
15	SKP2	S-Phase Kinase Associated Protein 2	Protein Coding	17.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19094580
16	KRT8	Keratin 8	Protein Coding	16.75	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17306351 18191996
17	MLH1	MutL Homolog 1	Protein Coding	15.74	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10769651
18	MMP14	Matrix Metallopeptidase 14	Protein Coding	14.63	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10366463 16425263
19	TP73	Tumor Protein P73	Protein Coding	14.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16818688
20	TIMP2	TIMP Metallopeptidase Inhibitor 2	Protein Coding	14.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10366463 16425263
21	CDH1	Cadherin 1	Protein Coding	13.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	EGFR	Epidermal Growth Factor Receptor	Protein Coding	13.67	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	CXCL14	C-X-C Motif Chemokine Ligand 14	Protein Coding	13.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10854217 15843547
24	CD40	CD40 Molecule	Protein Coding	13.12	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16142355
25	PTEN	Phosphatase And Tensin Homolog	Protein Coding	12.86	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
26	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	12.78	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
27	MMP2	Matrix Metallopeptidase 2	Protein Coding	12.66	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	CCND1	Cyclin D1	Protein Coding	12.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	KRT17	Keratin 17	Protein Coding	12.28	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
30	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	12.28	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
31	FAT1	FAT Atypical Cadherin 1	Protein Coding	12.18	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
32	EP300	E1A Binding Protein P300	Protein Coding	12.04	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
33	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	11.86	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
34	BSG	Basigin (Ok Blood Group)	Protein Coding	11.8	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	KMT2C	Lysine Methyltransferase 2C	Protein Coding	11.75	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
36	SMAD4	SMAD Family Member 4	Protein Coding	11.64	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
37	KMT2D	Lysine Methyltransferase 2D	Protein Coding	11.5	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
38	SERPINB4	Serpin Family B Member 4	Protein Coding	11.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
39	DDX3X	DEAD-Box Helicase 3 X-Linked	Protein Coding	10.97	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
40	JAG1	Jagged Canonical Notch Ligand 1	Protein Coding	10.9	DISEASES inferred ¹⁴ GeneCards inferred via : Expressions (show sections)
41	MKI67	Marker Of Proliferation Ki-67	Protein Coding	10.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18561741 10752690 18942401 (more) 15891905
42	KRT14	Keratin 14	Protein Coding	9.93	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12657108
43	CDKN1B	Cyclin Dependent Kinase Inhibitor 1B	Protein Coding	9.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16677523 15143339
44	EGF	Epidermal Growth Factor	Protein Coding	9.38	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9817979 10545752
45	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	9.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11876385
46	STAT1	Signal Transducer And Activator Of Transcription 1	Protein Coding	9.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17306351
47	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	8.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14557015 17360030
48	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	8.77	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16677523
49	FHIT	Fragile Histidine Triad Diadenosine Triphosphatase	Protein Coding	8.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10745171
50	KRT10	Keratin 10	Protein Coding	8.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7522949

Sources

Variations for Cervical Squamous Cell Carcinoma

Cosmic variations for Cervical Squamous Cell Carcinoma:

⁸ (show top 50) (show all 907)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM123189243	UTP23	cervix,NS,carcinoma,squamous cell carcinoma	c.270G>A	p.L90=	8:116848969-116848969	10
2	COSM127848324	UTP23	cervix,NS,carcinoma,squamous cell carcinoma	c.127G>A	p.E43K	8:116848969-116848969	10
3	COSM123189233	UTP23	cervix,NS,carcinoma,squamous cell carcinoma	c.249G>A	p.L83=	8:116848948-116848948	10
4	COSM127848316	UTP23	cervix,NS,carcinoma,squamous cell carcinoma	c.106G>A	p.E36K	8:116848948-116848948	10
5	COSM101184918	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4630C>G	p.L1544V	16:2086857-2086857	10
6	COSM90408532	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4906C>G	p.L1636V	16:2086857-2086857	10
7	COSM149806850	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4843C>G	p.L1615V	16:2086857-2086857	10
8	COSM87033167	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4975C>G	p.L1659V	16:2086857-2086857	10
9	COSM151515645	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4900C>G	p.L1634V	16:2086857-2086857	10
10	COSM150318236	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4774C>G	p.L1592V	16:2086857-2086857	10
11	COSM102623419	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4774C>G	p.L1592V	16:2086857-2086857	10
12	COSM151373080	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4969C>G	p.L1657V	16:2086857-2086857	10
13	COSM150359241	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4771C>G	p.L1591V	16:2086857-2086857	10
14	COSM151750121	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4846C>G	p.L1616V	16:2086857-2086857	10
15	COSM110108009	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4666C>G	p.L1556V	16:2086857-2086857	10
16	COSM148986154	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4777C>G	p.L1593V	16:2086857-2086857	10
17	COSM136621744	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4807C>G	p.L1603V	16:2086857-2086857	10
18	COSM150579385	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4768C>G	p.L1590V	16:2086857-2086857	10
19	COSM147699343	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4846C>G	p.L1616V	16:2086857-2086857	10
20	COSM122748443	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.434G>T	p.C145F	17:7673790-7673790	10
21	COSM93517877	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.868C>A	p.R290S	17:7673752-7673752	10
22	COSM144129341	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.242G>T	p.S81I	17:7674244-7674244	10
23	COSM143944858	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.109C>T	p.R37*	17:7674945-7674945	10
24	COSM144310445	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.700C>T	p.R234C	17:7673803-7673803	10
25	COSM121892294	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.434G>T	p.C145F	17:7673790-7673790	10
26	COSM143371865	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.469C>T	p.R157*	17:7674945-7674945	10
27	COSM145017326	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.407G>A	p.R136H	17:7675088-7675088	10
28	COSM143156696	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.224A>G	p.Y75C	17:7674262-7674262	10
29	COSM143157606	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.109C>T	p.R37*	17:7674945-7674945	10
30	COSM142566486	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.701G>C	p.R234P	17:7673802-7673802	10
31	COSM122734408	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.421C>T	p.R141C	17:7673803-7673803	10
32	COSM121883974	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.422G>C	p.R141P	17:7673802-7673802	10
33	COSM144086975	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.47G>A	p.R16H	17:7675088-7675088	10
34	COSM144653059	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.310G>A	p.V104M	17:7675185-7675185	10
35	COSM88036027	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.775G>C	p.D259H	17:7674188-7674188	10
36	COSM145017959	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.700C>T	p.R234C	17:7673803-7673803	10
37	COSM143943866	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.59A>G	p.H20R	17:7675076-7675076	10
38	COSM143168691	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.353G>T	p.C118F	17:7673790-7673790	10
39	COSM121894970	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.452G>A	p.R151H	17:7673772-7673772	10
40	COSM142846443	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.550G>A	p.D184N	17:7675062-7675062	10
41	COSM121875983	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.347G>A	p.R116Q	17:7674220-7674220	10
42	COSM143370595	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.407G>A	p.R136H	17:7675088-7675088	10
43	COSM143370869	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.626G>A	p.R209Q	17:7674220-7674220	10
44	COSM106069893	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.848G>A	p.R283H	17:7673772-7673772	10
45	COSM145017657	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.626G>A	p.R209Q	17:7674220-7674220	10
46	COSM112308199	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.719G>T	p.S240I	17:7674244-7674244	10
47	COSM143376130	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.329G>C	p.S110T	17:7673814-7673814	10
48	COSM143422228	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.602G>T	p.S201I	17:7674244-7674244	10
49	COSM143384418	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.433G>A	p.D145N	17:7675062-7675062	10
50	COSM144024948	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.517G>A	p.D173N	17:7675062-7675062	10

Copy number variations for Cervical Squamous Cell Carcinoma from CNVD:

⁶ (show all 38)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	191444	5	1	15100000	Gain	PDCD6	Cervical squamous cell carcinoma
2	191466	5	1	18500000	Gain	TENT4A	Cervical squamous cell carcinoma
3	191467	5	1	18500000	Gain	SDHA	Cervical squamous cell carcinoma
4	191468	5	1	18500000	Gain	SRD5A1	Cervical squamous cell carcinoma
5	191624	5	1	42400000	Gain	RPL37	Cervical squamous cell carcinoma
6	191625	5	1	42400000	Gain	SKP2	Cervical squamous cell carcinoma
7	191627	5	1	42400000	Gain	SLC1A3	Cervical squamous cell carcinoma
8	191642	5	1	4400000	Gain	IRX2	Cervical squamous cell carcinoma
9	191643	5	1	4400000	Gain	NDUFS6	Cervical squamous cell carcinoma
10	191644	5	1	4400000	Gain	TERT	Cervical squamous cell carcinoma
11	191646	5	1	4400000	Gain	TRIP13	Cervical squamous cell carcinoma
12	191726	5	1	8200000	Gain	IRX4	Cervical squamous cell carcinoma
13	195451	5	15100000	18500000	Gain	ANKH	Cervical squamous cell carcinoma
14	195452	5	15100000	18500000	Gain	ZNF622	Cervical squamous cell carcinoma
15	195453	5	15100000	23300000	Gain	MYO10	Cervical squamous cell carcinoma
16	195454	5	15100000	29300000	Gain	BASP1	Cervical squamous cell carcinoma
17	198725	5	29300000	34400000	Gain	DROSHA	Cervical squamous cell carcinoma
18	198726	5	29300000	34400000	Gain	GOLPH3	Cervical squamous cell carcinoma
19	198727	5	29300000	34400000	Gain	MTMR12	Cervical squamous cell carcinoma
20	198728	5	29300000	34400000	Gain	SUB1	Cervical squamous cell carcinoma
21	199076	5	34400000	38500000	Gain	DNAJC21	Cervical squamous cell carcinoma
22	199078	5	34400000	38500000	Gain	LMBRD2	Cervical squamous cell carcinoma
23	199079	5	34400000	38500000	Gain	NIPBL	Cervical squamous cell carcinoma
24	199080	5	34400000	38500000	Gain	RAD1	Cervical squamous cell carcinoma
25	199082	5	34400000	38500000	Gain	TARS1	Cervical squamous cell carcinoma
26	199083	5	34400000	38500000	Gain	WDR70	Cervical squamous cell carcinoma
27	199384	5	38500000	42400000	Gain	NUP155	Cervical squamous cell carcinoma
28	199385	5	38500000	42400000	Gain	OXCT1	Cervical squamous cell carcinoma
29	199684	5	42400000	45800000	Gain	CCL28	Cervical squamous cell carcinoma
30	199685	5	42400000	45800000	Gain	FBXO4	Cervical squamous cell carcinoma
31	199686	5	42400000	45800000	Gain	PAIP1	Cervical squamous cell carcinoma
32	199689	5	42400000	47700000	Gain	ZNF131	Cervical squamous cell carcinoma
33	199835	5	4400000	6000000	Gain	ICE1	Cervical squamous cell carcinoma
34	202451	5	8200000	15100000	Gain	CCT5	Cervical squamous cell carcinoma
35	202452	5	8200000	15100000	Gain	DAP	Cervical squamous cell carcinoma
36	202454	5	8200000	15100000	Gain	MARCHF6	Cervical squamous cell carcinoma
37	202462	5	8200000	23300000	Gain	ZFYVE16	Cervical squamous cell carcinoma
38	202464	5	8200000	45800000	Gain	TTC33	Cervical squamous cell carcinoma

Sources

Expression for Cervical Squamous Cell Carcinoma

Genes differentially expressed in tissues of Cervical Squamous Cell Carcinoma patients vs. healthy controls: ³⁵ (show all 33)

#	Gene	Description	Tissue	Up/Dn	Fold Change (log2)	P value
1	CRNN	cornulin	Uterus	-	5.62	0.000
2	KRT1	keratin 1	Uterus	-	5.32	0.000
3	UPK1A	uroplakin 1A	Uterus	-	4.79	0.000
4	MAL	mal, T cell differentiation protein	Uterus	-	4.73	0.000
5	KRT4	keratin 4	Uterus	-	4.45	0.000
6	SPRR3	small proline rich protein 3	Uterus	-	4.43	0.000
7	DSG1	desmoglein 1	Uterus	-	4.27	0.000
8	CDKN2A	cyclin dependent kinase inhibitor 2A	Uterus	+	4.21	0.000
9	CRISP3	cysteine rich secretory protein 3	Uterus	-	4.13	0.000
10	CRCT1	cysteine rich C-terminal 1	Uterus	-	3.92	0.000
11	SPINK5	serine peptidase inhibitor Kazal type 5	Uterus	-	3.67	0.000
12	SLURP1	secreted LY6/PLAUR domain containing 1	Uterus	-	3.54	0.000
13	APOC1	apolipoprotein C1	Uterus	+	3.53	0.000
14	HOPX	HOP homeobox	Uterus	-	3.51	0.000
15	EDN3	endothelin 3	Uterus	-	3.48	0.000
16	FANCI	FA complementation group I	Uterus	+	3.42	0.000
17	SYNGR3	synaptogyrin 3	Uterus	+	3.41	0.000
18	CRYAB	crystallin alpha B	Uterus	-	3.39	0.000
19	KRT13	keratin 13	Uterus	-	3.35	0.004
20	MCM5	minichromosome maintenance complex component 5	Uterus	+	3.31	0.000
21	ALOX12	arachidonate 12-lipoxygenase, 12S type	Uterus	-	3.26	0.000
22	PPP1R3C	protein phosphatase 1 regulatory subunit 3C	Uterus	-	3.23	0.000
23	SCEL	sciellin	Uterus	-	3.19	0.000
24	NTS	neurotensin	Uterus	+	3.19	0.006
25	NUSAP1	nucleolar and spindle associated protein 1	Uterus	+	3.17	0.000
26	IVL	involucrin	Uterus	-	3.14	0.000
27	IL1R2	interleukin 1 receptor type 2	Uterus	-	3.14	0.000
28	CFD	complement factor D	Uterus	-	3.13	0.000
29	SOSTDC1	sclerostin domain containing 1	Uterus	-	3.08	0.000
30	ESR1	estrogen receptor 1	Uterus	-	3.06	0.000
31	PAMR1	peptidase domain containing associated with muscle regeneration 1	Uterus	-	3.06	0.000
32	ENDOU	endonuclease, poly(U) specific	Uterus	-	3.04	0.000
33	HOXC6	homeobox C6	Uterus	+	3.01	0.000

Search GEO for disease gene expression data for Cervical Squamous Cell Carcinoma.

Sources

Pathways for Cervical Squamous Cell Carcinoma

Pathways related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 18)

#	Super pathways	Score	Top Affiliating Genes
1	Regulation of TP53 Activity ⁶⁶ Show member pathways Regulation of TP53 Activity through Association with Co-factors ⁶⁶ Regulation of TP53 Activity through Methylation ⁶⁶ Regulation of TP53 Activity through Phosphorylation ⁶⁶ Transcriptional Regulation by TP53 ⁶⁶	12.78	TP73 TP63 TP53 MLH1 CDKN2A
2	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis ⁷⁴ Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis modulation by HSP70 ⁷⁴ Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ Ceramide signaling pathway ⁶¹ DR3 Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef: Negative effector of Fas and TNF-alpha ⁶¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF Signaling ⁶⁴ TNF-related weak inducer of apoptosis (TWEAK) signaling pathway ⁷⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	12.75	TP73 TP63 TP53 PIK3CA DAPK1 CDKN2A
3	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.53	TP53 RASSF1 PIK3CA MLH1 CDKN2A
4	Malignant pleural mesothelioma ⁷⁴	12.5	TP53 RASSF1 PIK3CA MMP14 CDKN2A
5	Programmed Cell Death ⁶⁶ Show member pathways Apoptosis ⁶⁶	12.43	TP73 TP63 TP53 DAPK1 CDKN2A
6	DNA Damage ³	12.1	TP73 TP63 TP53 SKP2 MLH1 CDKN2A
7	Intrinsic Pathway for Apoptosis ⁶⁶ Show member pathways Activation of BAD and translocation to mitochondria ⁶⁶ Activation of BH3-only proteins ⁶⁶ Activation of BIM and translocation to mitochondria ⁶⁶ Activation of BMF and translocation to mitochondria ⁶⁶ Activation of NOXA and translocation to mitochondria ⁶⁶ Activation of PUMA and translocation to mitochondria ⁶⁶ Activation, myristolyation of BID and translocation to mitochondria ⁶⁶ Apoptotic factor-mediated response ⁶⁶ BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members ⁶⁶ Cytochrome c-mediated apoptotic response ⁶⁶ Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function ⁶⁶ Release of apoptotic factors from the mitochondria ⁶⁶ SMAC, XIAP-regulated apoptotic response ⁶⁶	12.04	TP73 TP63 TP53 CDKN2A
8	Direct p53 effectors ⁶¹	11.81	TP73 TP63 TP53 MLH1
9	Senescence and autophagy in cancer ⁷⁴	11.76	TP53 MMP14 CDKN2A
10	TP53 Regulates Transcription of Cell Death Genes ⁶⁶ Show member pathways The IPAF inflammasome ⁶⁶ TP53 Regulates Transcription of Caspase Activators and Caspases ⁶⁶ TP53 Regulates Transcription of Death Receptors and Ligands ⁶⁶ TP53 Regulates Transcription of Genes Involved in Cytochrome C Release ⁶⁶ TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain ⁶⁶	11.74	TP73 TP63 TP53
11	DNA damage response (only ATM dependent) ⁷⁴	11.72	TP73 TP53 PIK3CA
12	DNA IR-double strand breaks and cellular response via ATM ⁷⁴ Show member pathways ATM pathway ⁶¹ DNA damage_DNA-damage-induced responses ²²	11.66	TP73 TP53 RASSF1 CDKN2A
13	Head and neck squamous cell carcinoma ⁷⁴	11.49	TP63 TP53 PIK3CA CDKN2A
14	Netrin-UNC5B signaling pathway ⁷⁴	11.35	DAPK1 PIK3CA TP53
15	p53 pathway ⁶¹	11.26	TP53 SKP2 RASSF1 CDKN2A
16	Hypoxic and oxygen homeostasis regulation of HIF-1-alpha ⁶¹	10.81	TP53 CDKN2A
17	Bladder cancer ⁷⁴	10.62	TYMP TP53 RASSF1 DAPK1 CDKN2A
18	TP53 network ⁷⁴ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	10.56	TP73 TP63 TP53 CDKN2A

Sources

GO Terms for Cervical Squamous Cell Carcinoma

Biological processes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cell cycle	GO:0007049	9.81	TP73 TP63 TP53 RASSF1 MLH1 CDKN2A
2	cellular senescence	GO:0090398	9.73	TP63 TP53 CDKN2A
3	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	GO:0042771	9.43	TP73 TP63 TP53
4	protein tetramerization	GO:0051262	9.1	TP73 TP63 TP53